These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Suitability of Trinidad/Tobago as a potential site for phase III efficacy studies of HIV-1 vaccines. Paul R; Cleghorn F; Jack N; Edwards J; Mahabir B; Murphy J; Blattner W; Bartholomew C AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S9. PubMed ID: 7865340 [No Abstract] [Full Text] [Related]
7. Statistical evaluation of HIV vaccines in early clinical trials. Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900 [TBL] [Abstract][Full Text] [Related]
8. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection. Fletcher PS; Shattock RJ Curr Opin Investig Drugs; 2008 Feb; 9(2):189-200. PubMed ID: 18246522 [TBL] [Abstract][Full Text] [Related]
9. HIV vaccines under study. Ravanfar P; Mendoza N; Satyaprakash A; Jordan BI Dermatol Ther; 2009; 22(2):158-67. PubMed ID: 19335727 [TBL] [Abstract][Full Text] [Related]
10. HIV vaccine efficacy trials: towards the future of HIV prevention. Kim D; Elizaga M; Duerr A Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236 [TBL] [Abstract][Full Text] [Related]
11. Role of therapeutic vaccines in the control of HIV-1. Kinloch-de Loes S J Antimicrob Chemother; 2004 Apr; 53(4):562-6. PubMed ID: 14985273 [TBL] [Abstract][Full Text] [Related]
12. HIV immunology: what lessons can we learn from recent vaccine trials? Kelleher P J HIV Ther; 2010 Mar; 15(1):2-5. PubMed ID: 21180231 [No Abstract] [Full Text] [Related]
13. [Ethical elements in the development of vaccines against HIV/AIDS]. Molina CN Sidahora; 2001 Oct; ():14-6. PubMed ID: 11776246 [No Abstract] [Full Text] [Related]
14. Human versus HIV: round 2 defeat in AIDS vaccine development. Lu S Expert Rev Vaccines; 2008 Mar; 7(2):151-3. PubMed ID: 18324884 [No Abstract] [Full Text] [Related]
15. Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. Graham BS; Mascola JR J Infect Dis; 2005 Mar; 191(5):647-9. PubMed ID: 15688276 [No Abstract] [Full Text] [Related]
16. Back to basics. Nat Med; 2009 Aug; 15(8):821. PubMed ID: 19661964 [No Abstract] [Full Text] [Related]
17. Human trials of experimental HIV vaccines. Burke DS AIDS; 1995; 9 Suppl A():S171-80. PubMed ID: 8819583 [No Abstract] [Full Text] [Related]
18. Italy launches clinical trial for HIV vaccine. Nature; 2008 Jul; 454(7204):564. PubMed ID: 18668075 [No Abstract] [Full Text] [Related]
19. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Dimitrov A Curr Opin Investig Drugs; 2007 Aug; 8(8):653-61. PubMed ID: 17668367 [TBL] [Abstract][Full Text] [Related]
20. First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants. Hurwitz JL; Lockey TD; Jones B; Freiden P; Sealy R; Coleman J; Howlett N; Branum K; Slobod KS AIDS; 2008 Jan; 22(1):149-51. PubMed ID: 18090404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]